Original title: Relocation of mortality 80%

On July 7th, Tengshengbo Pharmaceutical and its holding company Teng Shenghua Chuang Pharmaceutical Technology (Beijing) Co., Ltd. announced that its long -acting new crown and antibody Ambellab and Romi Siwei's combination therapy was commercialized in China Listing.

It is understood that Anbawei's Mipide and Lemis Weimab are Teng Shengbo Pharmaceuticals and Shenzhen Third People's Hospital and Tsinghua University from the new type of coronary virus pneumonia (COVID-19) for rehabilitation. The acute respiratory syndrome virus 2 (SARS-COV-2) monoclonal neutral and antibodies, especially the biological engineering technology to reduce the risk of antibody media-to-dependence enhancement, and extend the half-life of the plasma to obtain a longer-lasting treatment effect.

On December 8, 2021, the National Infectious Disease Clinical Medicine Center, Shenzhen Third People's Hospital and Tsinghua University, and Teng Shengbo Pharmaceuticals developed a new crown monoclonal neutral and antibody Ambell monoclonal anti -anti -anti -anti -anti -anti -anti -resistance joint Therapy (previously called BRII-196/BRII-198 combination therapy) was approved by the China Drug Administration (NMPA).

This is the first approved autonomous intellectual property new coronary virus neutralized and antibody combined therapy drugs.

This drug is used to treat patients and teenagers (12-17 years old, weight ≥40 kg) with high-risk factors (including hospitalization or death) high-risk factor (including hospitalization or death). Among them, the adolescents (12-17 years old, weight ≥40 kg) are approved by the attachment.

According to the previously announced data, the main endpoint assessment and key data analysis instructions of all the subjects followed the 28 days of follow-up are consistent with the results of the mid-term analysis and conclusions.，It is statistically significant.